Drugs / AZD0305
last change Dec 2023 re-read 2 minutes ago

AZD0305

Developed for
plasma cell myeloma
Investigated by
AstraZeneca

Trials 1 · a red edge is where a trial was stopped

2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06106945 Dec 2023 → Aug 2027 expected plasma cell myeloma AstraZeneca Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as AZD0305 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06106945